

DCF Psychotropic Medication Advisory Committee
Meeting Minutes
December 11, 2023, 1:00 PM

PRESENT via Video Conference: Paul Rao, MD; Carissa Patsky-Pomerleau, MD; Naomi Libby, MD; Nicole Taylor, MD; Amy Veivia, PharmD; Hyesil Adams, APRN; Tina Spokes, RN; Angela Ojide, APRN

1. The meeting was held remotely via Zoom; Dr. Rao called the meeting to order at 1:05pm.
2. The minutes of the September 2023 meeting were reviewed and approved.
3. New Business: There was no new business to discuss. Dr. Taylor invited non-DCF members to propose agenda items for future meetings. A. Veivia will send an email to the group requesting the same.
4. Standing Agenda Items
 - a. Review of guidelines
 - i. Stimulant Medications: The committee reviewed the proposed revisions to the monitoring guidelines for stimulant medications. Most suggested changes were minor and related to formatting. It was noted that the monitoring of CBCs for methylphenidate was moved from "Follow-Up Studies" to "Special Considerations" as clinically indicated. The committee approved the revisions as presented.
 - ii. Review of medications being considered for addition to the approved medication list: Information was included in the guidelines for the stimulant formulations of Jornay, Azstarys, and Xelstrym. It was noted that Jornay and Azstarys have been reviewed by the committee in the past and not added to the approved drug list as there was limited experience with those medications at the time of review. It was also noted that of the 3 newer formulations, Jornay is the most requested. A motion was made to add these formulations to the approved drug list. Following a vote, the committee recommended the additions of Jornay, Azstarys, and Xelstrym to the approved medication list for DCF committed youth.
 - iii. Non-stimulant ADHD Medications: The committee reviewed proposed revisions to the monitoring guidelines for the non-stimulant ADHD medications. These proposed revisions were minor and related to formatting. Bupropion was removed from this section of the guidelines as it is represented in the antidepressant section. The committee approved the revisions as presented.
 - iv. Revised monitoring guidelines for "Typical" or first-generation antipsychotics were reviewed by the committee. These revisions proposed substantive differences from the guidelines for second-

generation antipsychotics, including that monitoring of certain metabolic indices are recommended as clinically indicated. Following discussion, the committee approved the revisions as presented.

- v. A. Veivia announced that Lithium and Anticonvulsants will be reviewed at the next meeting.

5. Other Business: There was no other business.

6. Dr. Rao adjourned the meeting at 2:00 PM. The next meeting is scheduled for March 11, 2024, from 1pm – 2:30pm via Zoom.

Respectfully submitted: Amy Veivia, PharmD

DRAFT